• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

CK5/6、p63、GATA6 和 HNF4a 的联合免疫组化预测治疗初治胰腺导管腺癌的临床结局。

Combination immunohistochemistry for CK5/6, p63, GATA6, and HNF4a predicts clinical outcome in treatment-naïve pancreatic ductal adenocarcinoma.

机构信息

Department of Pathology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo, 181-8611, Japan.

Department of Gastroenterology and Hepatology, Kyorin University School of Medicine, Tokyo, Japan.

出版信息

Sci Rep. 2024 Jul 6;14(1):15598. doi: 10.1038/s41598-024-65900-w.

DOI:10.1038/s41598-024-65900-w
PMID:38971768
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11227498/
Abstract

Although sequence-based studies show that basal-like features lead to worse prognosis and chemotherapy-resistance compared to the classical subtype in advanced pancreatic ductal adenocarcinoma (PDAC), a surrogate biomarker distinguishing between these subtypes in routine diagnostic practice remains to be identified. We aimed to evaluate the utility of immunohistochemistry (IHC) expression subtypes generated by unsupervised hierarchical clustering based on staining scores of four markers (CK5/6, p63, GATA6, HNF4a) applied to endoscopic ultrasound-guided fine needle aspiration biopsy (EUS-FNAB) materials. EUS-FNAB materials taken from 190 treatment-naïve advanced PDAC patients were analyzed, and three IHC patterns were established (Classical, Transitional, and Basal-like pattern). Basal-like pattern (high co-expression of CK5/6 and p63 with low expression of GATA6 and HNF4a) was significantly associated with squamous differentiation histology (p < 0.001) and demonstrated the worst overall survival among our cohort (p = 0.004). IHC expression subtype (Transitional, Basal vs Classical) was an independent poor prognosticator in multivariate analysis [HR 1.58 (95% CI 1.01-2.38), p = 0.047]. Furthermore, CK5/6 expression was an independent poor prognostic factor in histological glandular type PDAC [HR 2.82 (95% CI 1.31-6.08), p = 0.008]. Our results suggest that IHC expression patterns successfully predict molecular features indicative of the Basal-like subgroup in advanced PDAC. These results provide the basis for appropriate stratification for therapeutic selection and prognostic estimation of advanced PDAC in a simplified manner.

摘要

虽然基于序列的研究表明,与经典亚型相比,基底样特征导致晚期胰腺导管腺癌(PDAC)的预后更差且对化疗耐药,但在常规诊断实践中仍需要确定区分这些亚型的替代生物标志物。我们旨在评估基于四个标志物(CK5/6、p63、GATA6、HNF4a)染色评分的无监督层次聚类生成的免疫组织化学(IHC)表达亚型在经内镜超声引导细针抽吸活检(EUS-FNAB)材料中的应用价值。分析了 190 名未经治疗的晚期 PDAC 患者的 EUS-FNAB 材料,并建立了三种 IHC 模式(经典型、过渡型和基底样型)。基底样型(CK5/6 和 p63 高表达,GATA6 和 HNF4a 低表达)与鳞状分化组织学显著相关(p<0.001),并且在我们的队列中总生存最差(p=0.004)。在多变量分析中,IHC 表达亚型(过渡型、基底样型与经典型)是独立的预后不良因素[HR 1.58(95%CI 1.01-2.38),p=0.047]。此外,CK5/6 表达在组织学腺型 PDAC 中是独立的预后不良因素[HR 2.82(95%CI 1.31-6.08),p=0.008]。我们的结果表明,IHC 表达模式成功预测了晚期 PDAC 中基底样亚组的分子特征。这些结果为晚期 PDAC 的治疗选择和预后评估提供了简化的分层依据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3013/11227498/0d7fe78fcb72/41598_2024_65900_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3013/11227498/755f97a9d25c/41598_2024_65900_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3013/11227498/b3aaec6dd3ce/41598_2024_65900_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3013/11227498/1598f1209093/41598_2024_65900_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3013/11227498/0d7fe78fcb72/41598_2024_65900_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3013/11227498/755f97a9d25c/41598_2024_65900_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3013/11227498/b3aaec6dd3ce/41598_2024_65900_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3013/11227498/1598f1209093/41598_2024_65900_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3013/11227498/0d7fe78fcb72/41598_2024_65900_Fig4_HTML.jpg

相似文献

1
Combination immunohistochemistry for CK5/6, p63, GATA6, and HNF4a predicts clinical outcome in treatment-naïve pancreatic ductal adenocarcinoma.CK5/6、p63、GATA6 和 HNF4a 的联合免疫组化预测治疗初治胰腺导管腺癌的临床结局。
Sci Rep. 2024 Jul 6;14(1):15598. doi: 10.1038/s41598-024-65900-w.
2
Dual and triple gene combinations of KRT5, KRT17, and S100A2 identify basal-like subtype of pancreatic ductal adenocarcinoma and correlate with survival outcome.KRT5、KRT17 和 S100A2 的双重和三重基因组合可鉴定胰腺导管腺癌的基底样亚型,并与生存结局相关。
FASEB J. 2024 Aug 15;38(15):e23867. doi: 10.1096/fj.202302484RR.
3
The value of GATA6 immunohistochemistry and computer-assisted diagnosis to predict clinical outcome in advanced pancreatic cancer.GATA6 免疫组织化学和计算机辅助诊断对预测晚期胰腺癌临床结局的价值。
Sci Rep. 2021 Jul 22;11(1):14951. doi: 10.1038/s41598-021-94544-3.
4
Transcriptome-based classification to predict FOLFIRINOX response in a real-world metastatic pancreatic cancer cohort.基于转录组的分类预测真实世界转移性胰腺癌队列中 FOLFIRINOX 的反应。
Transl Res. 2024 Nov;273:137-147. doi: 10.1016/j.trsl.2024.08.002. Epub 2024 Aug 21.
5
GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer.GATA6 表达可区分晚期胰腺癌中的经典型和基底样亚型。
Clin Cancer Res. 2020 Sep 15;26(18):4901-4910. doi: 10.1158/1078-0432.CCR-19-3724. Epub 2020 Mar 10.
6
Morphological and p40 immunohistochemical analysis of squamous differentiation in endoscopic ultrasound guided fine needle biopsies of pancreatic ductal adenocarcinoma.内镜超声引导下细针穿刺活检胰腺导管腺癌中鳞状分化的形态学和 p40 免疫组织化学分析。
Sci Rep. 2021 Oct 28;11(1):21290. doi: 10.1038/s41598-021-00652-5.
7
TET2 Drives 5hmc Marking of GATA6 and Epigenetically Defines Pancreatic Ductal Adenocarcinoma Transcriptional Subtypes.TET2 驱动 5hmc 标记 GATA6 并在表观遗传上定义胰腺导管腺癌转录亚型。
Gastroenterology. 2021 Aug;161(2):653-668.e16. doi: 10.1053/j.gastro.2021.04.044. Epub 2021 Apr 27.
8
HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer.HNF4A和GATA6缺失揭示了胰腺癌中具有治疗可行性的亚型。
Cell Rep. 2020 May 12;31(6):107625. doi: 10.1016/j.celrep.2020.107625.
9
GATA6 identifies an immune-enriched phenotype linked to favorable outcomes in patients with pancreatic cancer undergoing upfront surgery.GATA6 鉴定出一种免疫富集表型,与接受初始手术的胰腺癌患者的良好预后相关。
Cell Rep Med. 2024 May 21;5(5):101557. doi: 10.1016/j.xcrm.2024.101557. Epub 2024 May 10.
10
Gene expression profiling of morphologic subtypes of pancreatic ductal adenocarcinoma using surgical and EUS-FNB specimens.应用手术和 EUS-FNB 标本对胰腺导管腺癌形态亚型的基因表达谱进行分析。
Pancreatology. 2021 Apr;21(3):530-543. doi: 10.1016/j.pan.2021.01.025. Epub 2021 Feb 9.

引用本文的文献

1
Drivers of Pancreatic Cancer: Beyond the Big 4.胰腺癌的驱动因素:超越四大因素
Cancers (Basel). 2025 Jul 15;17(14):2354. doi: 10.3390/cancers17142354.
2
Advancing Precision Medicine in PDAC: An Ethical Scoping Review and Call to Action for IHC Implementation.推进胰腺癌的精准医学:免疫组化实施的伦理范围审查及行动呼吁
Cancers (Basel). 2025 Jun 6;17(12):1899. doi: 10.3390/cancers17121899.
3
Primary lung adenocarcinoma harboring upper mediastinal lymphatic skip metastasis of cervical squamous cell carcinoma: A case report and literature review.

本文引用的文献

1
GATA6 and CK5 Stratify the Survival of Patients With Pancreatic Cancer Undergoing Neoadjuvant Chemotherapy.GATA6 和 CK5 可预测接受新辅助化疗的胰腺癌患者的生存情况。
Mod Pathol. 2023 May;36(5):100102. doi: 10.1016/j.modpat.2023.100102. Epub 2023 Jan 14.
2
GATA4 and GATA6 loss-of-expression is associated with extinction of the classical programme and poor outcome in pancreatic ductal adenocarcinoma.GATA4和GATA6表达缺失与胰腺导管腺癌中经典程序的消失及不良预后相关。
Gut. 2023 Mar;72(3):535-548. doi: 10.1136/gutjnl-2021-325803. Epub 2022 Sep 15.
3
A unifying paradigm for transcriptional heterogeneity and squamous features in pancreatic ductal adenocarcinoma.
伴有宫颈鳞状细胞癌上纵隔淋巴跳跃转移的原发性肺腺癌:一例报告及文献复习
Oncol Lett. 2024 Aug 7;28(4):481. doi: 10.3892/ol.2024.14614. eCollection 2024 Oct.
转录异质性和胰腺导管腺癌鳞状特征的统一范式。
Nat Cancer. 2020 Jan;1(1):59-74. doi: 10.1038/s43018-019-0010-1. Epub 2020 Jan 13.
4
The value of GATA6 immunohistochemistry and computer-assisted diagnosis to predict clinical outcome in advanced pancreatic cancer.GATA6 免疫组织化学和计算机辅助诊断对预测晚期胰腺癌临床结局的价值。
Sci Rep. 2021 Jul 22;11(1):14951. doi: 10.1038/s41598-021-94544-3.
5
A GATA6-centred gene regulatory network involving HNFs and ΔNp63 controls plasticity and immune escape in pancreatic cancer.一个以 GATA6 为中心的基因调控网络,涉及 HNFs 和 ΔNp63,控制着胰腺癌的可塑性和免疫逃逸。
Gut. 2022 Apr;71(4):766-777. doi: 10.1136/gutjnl-2020-321397. Epub 2021 Apr 12.
6
Reciprocal regulation of pancreatic ductal adenocarcinoma growth and molecular subtype by HNF4α and SIX1/4.HNF4α 和 SIX1/4 对胰腺导管腺癌生长和分子亚型的相互调节。
Gut. 2021 May;70(5):900-914. doi: 10.1136/gutjnl-2020-321316. Epub 2020 Aug 21.
7
HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer.HNF4A和GATA6缺失揭示了胰腺癌中具有治疗可行性的亚型。
Cell Rep. 2020 May 12;31(6):107625. doi: 10.1016/j.celrep.2020.107625.
8
The Evolutionary Origins of Recurrent Pancreatic Cancer.复发性胰腺癌的进化起源。
Cancer Discov. 2020 Jun;10(6):792-805. doi: 10.1158/2159-8290.CD-19-1508. Epub 2020 Mar 19.
9
GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer.GATA6 表达可区分晚期胰腺癌中的经典型和基底样亚型。
Clin Cancer Res. 2020 Sep 15;26(18):4901-4910. doi: 10.1158/1078-0432.CCR-19-3724. Epub 2020 Mar 10.
10
Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution.胰腺癌的转录表型是由肿瘤进化过程中的基因组事件驱动的。
Nat Genet. 2020 Feb;52(2):231-240. doi: 10.1038/s41588-019-0566-9. Epub 2020 Jan 13.